# Low-dose Combination of Three Antihypertensive Drugs

Study · id `cardio:ct-nct02710552` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02710552](<https://clinicaltrials.gov/study/NCT02710552>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02710552

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT02710552. Randomized; single masking; primary purpose treatment. Start 2016-04 (registry gives no type); primary completion 2019-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT02710552, source copy `cardio:ctgov-nct02710552-2016-03-17`, retrieved 2026-10-26)
- Start date: 2016-04 (registry gives no type) (ClinicalTrials.gov record NCT02710552, source copy `cardio:ctgov-nct02710552-2016-03-17`, retrieved 2026-10-26)
- Primary completion: 2019-03 (anticipated) (ClinicalTrials.gov record NCT02710552, source copy `cardio:ctgov-nct02710552-2016-03-17`, retrieved 2026-10-26)
- Completion: 2020-03 (anticipated) (ClinicalTrials.gov record NCT02710552, source copy `cardio:ctgov-nct02710552-2016-03-17`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT02710552, source copy `cardio:ctgov-nct02710552-2016-03-17`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02710552-2016-03-17`, retrieved 2026-10-26)

## The registry's words

- Brief title: Low-dose Combination of Three Antihypertensive Drugs
- Acronym: 3D
- Condition: Arterial Hypertension
- Intervention (Drug): Tripliam (perindopril, indapamide, amlodipine)
- Intervention (Drug): Reaptan (perindopril, amlodipine)
- Lead sponsor: University of Roma La Sapienza
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: University of Roma La Sapienza (`cardio:org-university-of-roma-la-sapienza`)

## Provenance

Content hash: 66385b77f66c3480338d8cee8098381c170b210802cb76f4b795bb89b189b3d7
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
